WO2008134445A3 - Platelet activation receptor clec-2: compositions and uses thereof - Google Patents

Platelet activation receptor clec-2: compositions and uses thereof Download PDF

Info

Publication number
WO2008134445A3
WO2008134445A3 PCT/US2008/061446 US2008061446W WO2008134445A3 WO 2008134445 A3 WO2008134445 A3 WO 2008134445A3 US 2008061446 W US2008061446 W US 2008061446W WO 2008134445 A3 WO2008134445 A3 WO 2008134445A3
Authority
WO
WIPO (PCT)
Prior art keywords
clec
podoplanin
compositions
disclosed
antibodies
Prior art date
Application number
PCT/US2008/061446
Other languages
French (fr)
Other versions
WO2008134445A8 (en
WO2008134445A2 (en
Inventor
Yukio Ozaki
Katsue Suzuki-Inoue
Yukinari Kato
Original Assignee
Univ Yamanashi
Yukio Ozaki
Katsue Suzuki-Inoue
Yukinari Kato
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yamanashi, Yukio Ozaki, Katsue Suzuki-Inoue, Yukinari Kato filed Critical Univ Yamanashi
Publication of WO2008134445A2 publication Critical patent/WO2008134445A2/en
Publication of WO2008134445A3 publication Critical patent/WO2008134445A3/en
Publication of WO2008134445A8 publication Critical patent/WO2008134445A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed are compositions comprising the platelet activation receptor C-type Lectin- like Receptor 2 (CLEC-2), and compositions comprising anti-CLEC-2 antibodies or antibodies that inhibit the interaction of CLEC-2 with podoplanin. Also disclosed are and methods of treating subjects in need thereof, comprising administering to the subject an effective amount of the disclosed compositions. Disclosed are recombinant CLEC-2 polypeptides, nucleic acids, antibodies, and compositions comprising recombinant CLEC-2 polypeptides, nucleic acids and antibodies. CLEC-2, has been found to interact with podoplanin. Recombinant CLEC-2 inhibits platelet aggregation induced by podoplanin- expressing tumor cells or lymphatic endothelial cells. Thus, CLEC-2 is responsible for platelet aggregation induced by endogenously expressed podoplanin on cell surfaces. CLEC- 2 is therefore a physiological target protein of podoplanin and is involved in podoplanin- induced platelet aggregation, tumor metastasis, and other cellular responses related to podoplanin. Disclosed are methods of treating, for instance, platelet aggregation-related disorders by administering effective amounts of the disclosed compositions to subjects in need thereof.
PCT/US2008/061446 2007-04-25 2008-04-24 Platelet activation receptor clec-2: compositions and uses thereof WO2008134445A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91390907P 2007-04-25 2007-04-25
US60/913,909 2007-04-25

Publications (3)

Publication Number Publication Date
WO2008134445A2 WO2008134445A2 (en) 2008-11-06
WO2008134445A3 true WO2008134445A3 (en) 2009-04-30
WO2008134445A8 WO2008134445A8 (en) 2009-07-30

Family

ID=39745183

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/061446 WO2008134445A2 (en) 2007-04-25 2008-04-24 Platelet activation receptor clec-2: compositions and uses thereof

Country Status (1)

Country Link
WO (1) WO2008134445A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2269597A1 (en) * 2009-06-22 2011-01-05 CSL Behring GmbH CLEC-2 is an essential platelet activating receptor in hemostasis and thrombosis
US20120095085A1 (en) * 2010-10-14 2012-04-19 Layzer Juliana M Nucleic acid modulators of clec-2
WO2012174534A2 (en) * 2011-06-17 2012-12-20 Amgen Inc. Method of treating or ameliorating metabolic disorders using clec-2
US20150258168A1 (en) * 2012-09-12 2015-09-17 Oklahoma Medical Research Foundation Modulation of podoplanin mediated platelet activation
EP3674324A4 (en) * 2017-03-30 2021-04-07 Tohoku University Anti-podoplanin antibody
CN108478783B (en) * 2018-03-30 2021-03-23 苏州大学 Application of CLEC-2 in preparation of medicines for treating craniocerebral injury

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KATSUE SUZUKI-INOUE ET AL: "Involvement of the Snake Toxin Receptor CLEC-2, in Podoplanin-mediated Platelet Activation, by Cancer Cells", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 282, no. 36, 6 July 2007 (2007-07-06), pages 25993 - 26001, XP009105651, ISSN: 0021-9258, [retrieved on 20070706] *

Also Published As

Publication number Publication date
WO2008134445A8 (en) 2009-07-30
WO2008134445A2 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
WO2008134445A8 (en) Platelet activation receptor clec-2: compositions and uses thereof
JOP20190017B1 (en) Human cgrp receptor binding antibodies
WO2014100439A3 (en) B7-h4 specific antibodies, and compositions and methods of use thereof
WO2006033854A3 (en) Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
WO2011140086A3 (en) Serum albumin binding molecules
WO2020077276A3 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
EP2447280A3 (en) VEGF analogs and methods of use
WO2009038760A3 (en) Human gm-csf antigen binding proteins
EA201170312A1 (en) SELECTIVE ANTIBODIES TO HEPCIDINE-25 AND THEIR APPLICATION
MX2008009886A (en) Antibodies that bind par-2.
WO2004078938A3 (en) Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2006073941A3 (en) Polypeptides that bind br3 and uses thereof
WO2007005786A3 (en) Methods and compositions with enhanced therapeutic activity
EP3670536A3 (en) Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof
WO2011060206A3 (en) Material and methods for treating or preventing her-3 associated diseases
MX2009013824A (en) Antigen binding proteins that bind par-2.
DK2343320T3 (en) ANTI-GITR ANTIBODIES AND APPLICATIONS THEREOF
WO2007025049A3 (en) Aptamers that bind thrombin with high affinity
WO2006036922A3 (en) Srage mimetibody, compositions, methods and uses
WO2006020060A3 (en) Iap binding compounds
BR112012031329A2 (en) vstm3 dimeric fusion proteins and related compositions and methods
ATE414725T1 (en) AMPHOTERELIC ETHYL METHACRYLATE COPOLYMERS AND USE THEREOF
MY153751A (en) Antibodies directed to her-3 and uses thereof
WO2006038027A3 (en) SINGLE DOMAIN ANTIBODIES AGAINST TNFRl AND METHODS OF USE THEREFOR
EA200801174A1 (en) GLP-2 MIMETIC ANTIBODIES, POLYPEPTIDES, COMPOSITIONS, METHODS AND APPLICATIONS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08746806

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08746806

Country of ref document: EP

Kind code of ref document: A2